SDZ 221-653

Discontinued Product

SDZ 221-653 (Cat. No. 1252) has been withdrawn from sale for commercial reasons.
Description: Less active enantiomer of (1250)
Chemical Name: (R)-a-Amino-2'-chloro-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid
Datasheet
Citations
Reviews
Literature (7)

Biological Activity for SDZ 221-653

Competitive NMDA antagonist (pKi = 6.3); less active enantiomer of SDZ 220-581 (cat.no. 1250).

Licensing Information

Sold with the permission of Novartis Pharma AG.

Technical Data for SDZ 221-653

M. Wt 369.74
Storage Store at RT
CAS Number 174575-18-9

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for SDZ 221-653

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

View Related Products by Target

Keywords: SDZ 221-653, SDZ 221-653 supplier, NMDA, Receptors, 1252, Tocris Bioscience

Citations for SDZ 221-653

Citations are publications that use Tocris products.

Currently there are no citations for SDZ 221-653.

Reviews for SDZ 221-653

There are currently no reviews for this product. Be the first to review SDZ 221-653 and earn rewards!

Have you used SDZ 221-653?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Ion Channel Product Listing

Ion Channel Product Listing

A collection of around 500 products for ion channel research, the listing includes research tools for the study of:

  • Ligand-gated ion channels
  • Voltage-gated ion channels
  • Other Ion Channels
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.